RD06-05 Universal CAR-T Therapy in Pediatric Autoimmune Diseases

Phase 1, open-label, single-arm trial of RD06-05 in systemic lupus erythematosus (SLE), lupus nephritis (LN), systemic sclerosis (SSc) and 3 more, sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoint: Incidence of Treatment-Emergent Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest at 24 months. Planned start Jul 2026; status: not yet recruiting.